The cancer research community based in Puget Sound region is on the spotlight. That is due to the recent visit of Joe Biden, Vice President of the United States. Seattle Genetics, a cancer drug company is part of what is making the region special with its rapid expansion. Located in Bothell, Seattle Genetics is trying to increase its drugs while widening the use of its initial drug. Additionally, it is on a hiring spree. The move shows the company’s ambitiousness. It also underscores Seattle’s major role as a leading cancer research region.
Seattle Genetics is trying out Adcetris, its only commercialized drug in several cancer treatment scenarios. According to CEO Clay Siegall, presently, the tests are being carried out in over 70 trials against several types of lymphomas. Particularly, the firm is carrying out a phase 3. It is an advanced clinical trial of Adcetris as a leading treatment for Hodgkin lymphoma that has been newly diagnosed or previously untreated. Siegall noted that the trials have had a major impact on the company.
Last year, Adcetris racked up $226 million in sales in the United States and Canada. In 2016, the sales projection for the drug that is mainly used to fight lymphomas is between $255 and $275 in the two countries. Adcetris is sold outside the United States and Canada by Takeda Pharmaceutical, the company’s partner.
Siegall noted that Adcetris is just one drug among the firm’s many. Seattle Genetics has 12 drugs that it is currently developing. This year, the firm wants to get an additional drug into Phase 3 clinical trials. The drug is called 33A. It will be used in treating acute myeloid leukemia. Additionally, Seattle Genetics has a drug for breast cancer as well as two drugs for bladder cancer. Siegall pointed out that in 2016, they will disseminate considerable information on the three drugs.
In the meantime, the firm is on a hiring spree. This year, it plans to add 100 professionals in the United States and nearly 20 for its Switzerland office. So far, the company has over 800 employees.
About Clay Siegall
Clay Siegall is the president and CEO of Seattle Genetics. He co-founded the cancer drug company in 1998. Siegall also serves as the company’s board chairman. He is a trained scientist that majored on targeted cancer therapies. Siegall established the firm on a strong foundation of rigorous research, scientific innovation, and drug development practices. He has led the company to become a leader in the development of antibody-drug conjugates for cancer treatment.